267 related articles for article (PubMed ID: 15325887)
1. Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3 mg drospirenone.
Bachmann G; Sulak PJ; Sampson-Landers C; Benda N; Marr J
Contraception; 2004 Sep; 70(3):191-8. PubMed ID: 15325887
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of a low-dose combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 mcg in a 24/4-day regimen.
Hernádi L; Marr J; Trummer D; De Leo V; Petraglia F
Contraception; 2009 Jul; 80(1):18-24. PubMed ID: 19501211
[TBL] [Abstract][Full Text] [Related]
3. A study of cycle control, side effects and client's satisfaction of a low dose combined contraceptive containing ethinylestradiol/drospirenone (24/4 regimen).
Chaiyasit N; Taneepanichskul S
J Med Assoc Thai; 2010 May; 93(5):517-22. PubMed ID: 20524436
[TBL] [Abstract][Full Text] [Related]
4. Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone.
Ahrendt HJ; Nisand I; Bastianelli C; Gómez MA; Gemzell-Danielsson K; Urdl W; Karskov B; Oeyen L; Bitzer J; Page G; Milsom I
Contraception; 2006 Dec; 74(6):451-7. PubMed ID: 17157101
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder.
Yonkers KA; Brown C; Pearlstein TB; Foegh M; Sampson-Landers C; Rapkin A
Obstet Gynecol; 2005 Sep; 106(3):492-501. PubMed ID: 16135578
[TBL] [Abstract][Full Text] [Related]
6. Bleeding profile of a flexible extended regimen of ethinylestradiol/drospirenone in US women: an open-label, three-arm, active-controlled, multicenter study.
Jensen JT; Garie SG; Trummer D; Elliesen J
Contraception; 2012 Aug; 86(2):110-8. PubMed ID: 22281416
[TBL] [Abstract][Full Text] [Related]
7. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
Cianci A; De Leo V
Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
[TBL] [Abstract][Full Text] [Related]
8. An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen.
Parsey KS; Pong A
Contraception; 2000 Feb; 61(2):105-11. PubMed ID: 10802275
[TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy and safety of a monophasic combined oral contraceptive containing 0.02 mg ethinylestradiol and 2 mg chlormadinone acetate administered in a 24/4-day regimen.
Brucker C; Hedon B; The HS; Höschen K; Binder N; Christoph A
Contraception; 2010 Jun; 81(6):501-9. PubMed ID: 20472117
[TBL] [Abstract][Full Text] [Related]
10. Effect of a combination of ethinylestradiol 30 microg and drospirenone 3 mg on tolerance, cycle control, general well-being and fluid-related symptoms in women with premenstrual disorders requesting contraception.
Borges LE; Andrade RP; Aldrighi JM; Guazelli C; Yazlle ME; Isaia CF; Petracco A; Peixoto FC; Camargos AF
Contraception; 2006 Dec; 74(6):446-50. PubMed ID: 17157100
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy and safety of a combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 µg in a 24+4-day regimen in China].
Caiyan W; Wen D; Qinping L; Huan S; Ziyan H; Liangdan T; Zheng'ai X; Yufeng L; Shulan Z; Baihua D; Xiaoyan X; Mulan R; Xiaomao L; Youdi X; Zhisong M; Meiqing X; Hongyu W; Zirong H
Zhonghua Fu Chan Ke Za Zhi; 2014 May; 49(5):355-9. PubMed ID: 25030732
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of a low-dose 21-day combined oral contraceptive containing ethinylestradiol 20microg and drospirenone 3mg.
Cibula D; Karck U; Weidenhammer HG; Kunz J; Alincic S; Marr J
Clin Drug Investig; 2006; 26(3):143-50. PubMed ID: 17163245
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of a new oral contraceptive containing drospirenone.
Shulman LP
J Reprod Med; 2002 Nov; 47(11 Suppl):981-4. PubMed ID: 12497672
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, safety, and tolerability of a monophasic oral contraceptive containing nomegestrol acetate and 17β-estradiol: a randomized controlled trial.
Westhoff C; Kaunitz AM; Korver T; Sommer W; Bahamondes L; Darney P; Verhoeven C
Obstet Gynecol; 2012 May; 119(5):989-99. PubMed ID: 22525910
[TBL] [Abstract][Full Text] [Related]
15. Contraceptive efficacy of a combined oral contraceptive containing ethinyloestradiol 20 μg/drospirenone 3mg administered in a 24/4 regimen: a pooled analysis of four open-label studies.
Anttila L; Bachmann G; Hernádi L; Kunz M; Marr J; Klipping C
Eur J Obstet Gynecol Reprod Biol; 2011 Apr; 155(2):180-2. PubMed ID: 21277674
[TBL] [Abstract][Full Text] [Related]
16. Nomegestrol acetate/estradiol: in oral contraception.
Yang LP; Plosker GL
Drugs; 2012 Oct; 72(14):1917-28. PubMed ID: 22950535
[TBL] [Abstract][Full Text] [Related]
17. Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: a randomized controlled trial.
Maloney JM; Dietze P; Watson D; Niknian M; Lee-Rugh S; Sampson-Landers C; Korner P
Obstet Gynecol; 2008 Oct; 112(4):773-81. PubMed ID: 18827119
[TBL] [Abstract][Full Text] [Related]
18. [Combined hormonal contraception in cycles artificially extended].
Bustillos-Alamilla E; Zepeda-Zaragoza J; Hernández-Ruiz MA; Briones-Landa CH
Ginecol Obstet Mex; 2010 Jan; 78(1):37-45. PubMed ID: 20931801
[TBL] [Abstract][Full Text] [Related]
19. Bleeding pattern, tolerance and patient satisfaction with a drospirenone-containing oral contraceptive evaluated in 3488 women in Europe, the Middle East and Canada.
Endrikat JS; Milchev NP; Kapamadzija A; Georgievska J; Gerlinger C; Schmidt W; Feroze S
Contraception; 2009 Jun; 79(6):428-32. PubMed ID: 19442777
[TBL] [Abstract][Full Text] [Related]
20. Yasmin: the reason why.
Thorneycroft IH
Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():13-8; discussion 42-3. PubMed ID: 12659402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
